Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

The clinical dilemma of RAASi therapy and hyperkalemia

10' education - Oct. 20, 2021 - Prof. Javed Butler, MD - Online CME

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD - Online CME

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD - Online CME

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Patient profiling in HFrEF to tailor therapy

5' education - June 21, 2021 - Pardeep Jhund, MD, PhD

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Introduction: Optimizing RAASi treatment through long-term potassium control

10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD

Novel potassium binders to improve management of chronic HF

10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME

Understanding risk of hyperkalemia in heart failure

10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME

Heart failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Relative fat mass most strongly associated with incident HF risk

Literature - Jan. 18, 2022 - Suthahar N et al. - Sci Rep. 2022

This study investigated the association between multiple indices of adiposity (both novel and established indices) and the risk of incident HF in a community-based cohort.

Epicardial adipose tissue associated with adverse outcomes in HFmrEF and HFpEF

Literature - Jan. 11, 2022 - Van Woerden G et al. - Circ Heart Fail. 2021

A study shows that epicardial adipose tissue volume is significantly associated with all-cause mortality and HF hospitalization in patients with HFmrEF and HFpEF.

Phase 3b trial with potassium binder in patients with HF meets primary endpoint

News - Dec. 22, 2021

The DIAMOND trial meets its primary endpoint and suggests that treatment with patiromer is beneficial to control serum potassium levels in HF patients with active hyperkalemia or history of hyperkalemia while treated with RAASi therapy.

Aspirin use associated with higher risk of incident fatal and non-fatal HF

Literature - Nov. 30, 2021 - Mujaj B et al. - ESC Heart Fail. 2021

This patient-level pooled analysis used data from 30 827 participants at risk of HF and showed that aspirin use was associated with a higher risk of incident fatal and non-fatal HF.

ARNI may reduce total heart failure events in patients with acute MI

Literature - Nov. 30, 2021 - Pfeffer MA, et al. - Circulation 2021

An exploratory analysis of the PARADISE-MI trial suggested that treatment with sacubitril/valsartan after an acute MI may reduce recurrent HF events compared to ramipril.

FDA New Drug Application and Priority Review for SGLT2i for HF across the full spectrum of ejection fraction

News - Nov. 23, 2021

The FDA has accepted a supplemental New Drug Application and granted Priority Review for empagliflozin for the treatment of adults with HF independent of LVEF.

SGLT2i reduces composite of CV death or HF hospitalization in HF patients with LVEF ≥50%

News - Nov. 17, 2021

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

SGLT2i improves symptoms in HF

News - Nov. 15, 2021

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

Transendocardial delivery of mesenchymal precursor cells in chronic HFrEF

News - Nov. 15, 2021

AHA 2021 This randomized, sham-controlled study showed that mesenchymal precursor cells did not reduce recurrent decompensated HF events. However, non-fatal MI or non-fatal stroke and decreased cardiac death were reduced in specific subgroups.

Initiation of SGLT2i associated with clinical benefit in acute HF

News - Nov. 14, 2021

AHA 2021 The EMPULSE trial showed that initiation of empagliflozin in patients hospitalized for acute HF resulted in a clinical benefit within 90 days, compared to placebo.

Statin therapy associated with reduced mortality in patients with HFpEF

Literature - Nov. 8, 2021 - Park CS et al. - ESC Heart Fail. 2021

This study investigated the effects of statin therapy on 5-year mortality in patients with acute HF and found that statin therapy was associated with reduced mortality in patients with HFpEF and in those with an ischemic etiology of HF.

SGLT2 inhibitor improves vascular function parameters in patients with HF

Literature - Nov. 1, 2021 - Kolwelter J et al. - ESC Heart Fail. 2021

This phase II randomized study showed that empagliflozin improved vascular function parameters in patients with HF under office conditions and in 24h ambulatory measurements compared to baseline as well as compared to placebo.